Pfizer is launching the first clinical trials for its PD-1xVEGF drug, while Akeso detailed the first overall survival win for ...

Eli Lilly expanded its AI drug discovery pact with XtalPi to antibodies. Celltrion in-licensed two innovative autoimmune ...

Artificial intelligence (AI) for science has rapidly gained momentum at an extreme pace. Models trained on the scientific record are generating hypotheses and even running experiments in automated ...

For rare diseases, AI-driven repurposing fills a critical gap. With more than 7000 rare diseases and only a small percentage ...

Eli Lilly will partner with Insilico Medicine on an artificial intelligence (AI)-based drug development collaboration that they said could generate “over $100 million” for the AI drug discovery ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding within Google parent company Alphabet, raising $600 million to advance its ...

Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm, led the ...

The Accreditation Council for Medical Affairs (ACMA) is raising the bar for excellence in life sciences by incorporating artificial intelligence training into its flagship certification, The Board ...

In drug discovery, scientists identify promising compounds and work to develop them into effective therapeutics. However, they often struggle to navigate expansive compound libraries and prioritize ...

Computational drug discovery and design integrates advanced computer‐aided methodologies with chemical and biological insights to accelerate the identification and optimisation of therapeutic agents.

The integration of artificial intelligence (AI) and machine learning (ML) in oncology clinical trials is rapidly evolving alongside the broader field. For example, AI-driven adaptive trial designs may ...